No Data
No Data
We Think Beijing Kawin Technology Share-Holding (SHSE:688687) Can Stay On Top Of Its Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' It's only natural to consider a company's balance sheet wh
Kellyne Technology (688687): Kailliwei's sales revenue increased by more than 200% year-on-year, and probiotic hepatitis B indications are progressing in an orderly manner
Sales revenue of the core product Kailiwei increased by more than 200% year over year. In 2023, the company achieved revenue of 1,412 billion yuan (+21.7% YoY), net profit attributable to mother of 117 million yuan (YoY +39.7%), after deducting net income from non-return to mother
Kain Technology (688687.SH): As of April 10, 2024, the number of shareholders of the company was 8,462
Gelonghui, April 15 | Kain Technology (688687.SH) said on the investor interactive platform that as of April 10, 2024, the number of shareholders of the company was 8,462.
Capital Securities released a research report on April 14 stating that it maintains Kain Technology (688687.SH) purchase rating. The main reasons for the rating include: 1) Kailiwei's revenue and profitability continue to increase, and Kim Shu-hee still h
Capital Securities released a research report on April 14 stating that it maintains Kain Technology (688687.SH) purchase rating. The main reasons for the rating include: 1) Kailiwei's revenue and profitability continue to increase, and Kim Shu-hee still has room for growth in the long term; 2) R&D of innovative drugs is progressing steadily, and long-term interferons are being implemented soon. (Mainichi Keizai Shimbun)
Kellyne Technology (688687): Kailiwei's rapid release drives rapid performance growth, long-acting interferon-derived probiotics completed phase III clinical trials
Incident Kain Technology Co., Ltd. released its 2023 annual report: achieved revenue of 1,412 billion yuan in 2023, an increase of 21.73% over the previous year; realized net profit of 117 million yuan, an increase of 39.71% over the previous year; deducted net income from non-return to mother
Kain Technology (688687): Contrary growth shows resilience and is optimistic that subsequent risks will be cleared
Short-term performance is under pressure. I am optimistic that subsequent risks will clear the company's revenue of 1,412 billion yuan (+21.73% yoy) in 23 years, which will return to the mother of 117 million yuan (+39.71% yoy); of these, 4Q23 achieved revenue of 4.1 billion yuan
No Data